Pharmasaga was established on January 25th, 2021, as a clinical drug development company. It is comprised of an experienced management team, a top-tier technical team, and a diverse group of specialized consultants. The Company aims to promote Taiwan's novel drug research and development to the global stage.

The Company currently has three product lines (pipelines), PS-001, PS-002, and PS-003, intended for the treatment of type 2 diabetes, type 1 diabetes, and cancer, respectively.

PS-001 is a first-in-class small-molecule drug for the treatment and reversal of type 2 diabetes. Preclinical trials are completed, and Phase I clinical trials are currently underway.

PS-002 is the same small-molecule drug used to treat type 1 diabetes. Preclinical trials are completed, and we are currently preparing for Phase II clinical trials.

PS-003 is a small-molecule drug for the treatment of cancer. Preclinical trials are currently being executed.

Pharmasaga

Org chart

Teams

Offices